These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12370065)

  • 1. Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors.
    Hilgeroth A
    Mini Rev Med Chem; 2002 Jun; 2(3):235-45. PubMed ID: 12370065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitors.
    Hilgeroth A; Lilie H
    Eur J Med Chem; 2003 May; 38(5):495-9. PubMed ID: 12767599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors.
    Hilgeroth A; Billich A
    Arch Pharm (Weinheim); 1999 Nov; 332(11):380-4. PubMed ID: 10605378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.
    Hilgeroth A; Wiese M; Billich A
    J Med Chem; 1999 Nov; 42(22):4729-32. PubMed ID: 10579836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.
    Hilgeroth A; Billich A; Lilie H
    Eur J Med Chem; 2001 Apr; 36(4):367-74. PubMed ID: 11461762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First bioanalytical evaluation of nonpeptidic cage dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H17: biotransformation and toxicity on Hep G2 cells.
    Hilgeroth A; Langner A
    Arch Pharm (Weinheim); 2000 Jan; 333(1):32-4. PubMed ID: 10675987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.
    Hilgeroth A; Billich A
    Arch Pharm (Weinheim); 1999 Jan; 332(1):3-5. PubMed ID: 10073137
    [No Abstract]   [Full Text] [Related]  

  • 8. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
    Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
    J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
    Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
    Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study.
    Hilgeroth A; Fleischer R; Wiese M; Heinemann FW
    J Comput Aided Mol Des; 1999 May; 13(3):233-42. PubMed ID: 10216831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
    Vara Prasad JV; Markoski LJ; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Holler T; Hupe D; Nouhan C; Gracheck SJ; VanderRoest S; Saunders J; Iyer K; Sinz M
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2217-22. PubMed ID: 10465549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioanalysis of syn dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H19: metabolic and cytotoxic properties in Hep G2 cells.
    Hilgeroth A; Langner A
    Arch Pharm (Weinheim); 2000 Jun; 333(6):195-7. PubMed ID: 10909192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization.
    Vidu A; Dufau L; Bannwarth L; Soulier JL; Sicsic S; Piarulli U; Reboud-Ravaux M; Ongeri S
    ChemMedChem; 2010 Nov; 5(11):1899-906. PubMed ID: 20936621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
    Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
    J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
    Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
    Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
    Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.